China Enhances Dope Management And ADR Systems
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China will forbid pharmaceutical and chemical companies in China from manufacturing, selling, trading, exporting and importing any anabolic agents without the government approval, and China's State FDA will improve the adverse drug reaction report system, SFDA said at a July 8 press conference